An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI <= 15 versus > 15-MedSci.cn

An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI <= 15 versus > 15

Foley, P; Gooderham, M; Gordon, K; Thaci, D; Kundu, S; Kisa, R; Wei, L; Banerjee, S

AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021; 62 (): 55

科室
- - 订阅+
  - 更多科室
工具
服务